Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
R PalaciosC Gómez-AyerbeJ L CasadoF TejerinaM L MontesM CastañoA OcampoD RialE RiberaM J GalindoC HidalgoC FariñasM MonteroT PayerasFrancisco FanjulJ de la TorreJ SantosPublished in: HIV medicine (2023)
This study confirms the effectiveness, tolerability and safety of DTG/RPV in real-world clinical practice in a different population from clinical trials, with many years of infection, low CD4 nadir, several previous treatment lines, more than half with virological failures, and one-third diagnosed with AIDS. The switch to DTG/RPV was safe with few discontinuations due to adverse effects. Modifications of the lipid and liver profiles were favourable. There were no relevant changes in kidney function.